Product / Service Summary

Tacalyx researches and develops therapeutics directed against TACAs (tumour-associated carbohydrate antigens). These strongly tumor-specific structures are synthesized by cancer cells and contribute significantly to its virulence and metastasis.


Chemicals/Pharmaceuticals

Seed Stage

Manufacturing

B2B

Description

The recent synthesis of these complex structures - TACAs (tumor-associated carbohydrate antigens) - allows the production of specific antibodies that can be used for the treatment of currently unsatisfactorily treatable cancers.


Tacalyx Funding


Tacalyx Team Members


Recent news about Tacalyx

26.09.2019

7 Mio. Euro für Berliner Start-up Tacalyx

Krebsforschung ist teuer: Ein hochkarätiges Konsortium europäischer Investoren finanziert den Start eines Biotechnologieunternehmens, das auf Forschungsergebnissen der Max-Planck-Gesellschaft aufbaut.

|transkript Read full article




Startbase Data

Added: 16.10.2019
Updated: 17.09.2020
  • Validated team members on Startbase
  • Registered at a German Handelsregister
  • Headquarter located in Germany
  • Scalable Business Model
  • Innovative Business Model

Tacalyx

Tacalyx is engaged in the development of human therapeutics.